Literature DB >> 11751106

Conversion of oxacillin-resistant staphylococci from heterotypic to homotypic resistance expression.

J E Finan1, A E Rosato, T M Dickinson, D Ko, Gordon L Archer.   

Abstract

Staphylococci that acquire the mecA gene are usually resistant to beta-lactam antibiotics (methicillin or oxacillin resistance). mecA encodes a penicillin-binding protein (PBP 2a) that has a reduced affinity for beta-lactams. In some isolates with methicillin or oxacillin resistance, only a small proportion (< or =0.1%) of the population expresses resistance to > or =10 microg of oxacillin per ml (heterotypic resistance [HeR]), while in other isolates most of the population expresses resistance (homotypic resistance [HoR]). In the present study, growth of Staphylococcus aureus or Staphylococcus epidermidis strains with HeR in concentrations of oxacillin (0.3 to 0.7 microg/ml) that produced a fall or a lag in optical density converted the strains from the HeR to the HoR phenotype. The conversion from the HeR to the HoR phenotype appeared to be due to the selection of a highly resistant mutant population, as determined by fluctuation analysis and the failure of populations with HoR to revert to HeR after 60 generations of growth in antibiotic-free media. The frequencies of conversion were as high as 10(-3) to 10(-2). Conversion to HoR required an intact mecA gene and an increase in the level of mecA transcription since no highly resistant subpopulation could be selected after growth in oxacillin when mecA transcription was constitutively repressed or when mecA had been inactivated. In addition, in both S. epidermidis and S. aureus the level of resistance to vancomycin, which also acts directly on the staphylococcal cell wall, was greater among convertants with HoR than their isogenic parents. The conversion of a population from HeR to HoR involves the selection of a mutation(s) that occurs at a high frequency and most likely requires abundant PBP 2a.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11751106      PMCID: PMC126971          DOI: 10.1128/AAC.46.1.24-30.2002

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  26 in total

1.  The molecular mechanism of phase variation of H. influenzae lipopolysaccharide.

Authors:  J N Weiser; J M Love; E R Moxon
Journal:  Cell       Date:  1989-11-17       Impact factor: 41.582

2.  Recombinational switch for gene expression.

Authors:  J Zieg; M Silverman; M Hilmen; M Simon
Journal:  Science       Date:  1977-04-08       Impact factor: 47.728

3.  Production of low-affinity penicillin-binding protein by low- and high-resistance groups of methicillin-resistant Staphylococcus aureus.

Authors:  K Murakami; K Nomura; M Doi; T Yoshida
Journal:  Antimicrob Agents Chemother       Date:  1987-09       Impact factor: 5.191

4.  Restriction maps of the regions coding for methicillin and tobramycin resistances on chromosomal DNA in methicillin-resistant staphylococci.

Authors:  K Ubukata; R Nonoguchi; M Matsuhashi; M D Song; M Konno
Journal:  Antimicrob Agents Chemother       Date:  1989-09       Impact factor: 5.191

5.  Genetic control of population structure in heterogeneous strains of methicillin resistant Staphylococcus aureus.

Authors:  H de Lencastre; A M Figueiredo; A Tomasz
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1993       Impact factor: 3.267

6.  Reassessment of the number of auxiliary genes essential for expression of high-level methicillin resistance in Staphylococcus aureus.

Authors:  H de Lencastre; A Tomasz
Journal:  Antimicrob Agents Chemother       Date:  1994-11       Impact factor: 5.191

7.  Increased amounts of a novel penicillin-binding protein in a strain of methicillin-resistant Staphylococcus aureus exposed to nafcillin.

Authors:  H F Chambers; B J Hartman; A Tomasz
Journal:  J Clin Invest       Date:  1985-07       Impact factor: 14.808

8.  Low-level methicillin resistance in strains of Staphylococcus aureus.

Authors:  H F Chambers; G Archer; M Matsuhashi
Journal:  Antimicrob Agents Chemother       Date:  1989-04       Impact factor: 5.191

9.  Expression of methicillin resistance in heterogeneous strains of Staphylococcus aureus.

Authors:  B J Hartman; A Tomasz
Journal:  Antimicrob Agents Chemother       Date:  1986-01       Impact factor: 5.191

10.  Dissemination among staphylococci of DNA sequences associated with methicillin resistance.

Authors:  G L Archer; D M Niemeyer; J A Thanassi; M J Pucci
Journal:  Antimicrob Agents Chemother       Date:  1994-03       Impact factor: 5.191

View more
  23 in total

1.  PBP2a mutations causing high-level Ceftaroline resistance in clinical methicillin-resistant Staphylococcus aureus isolates.

Authors:  S Wesley Long; Randall J Olsen; Shrenik C Mehta; Timothy Palzkill; Patricia L Cernoch; Katherine K Perez; William L Musick; Adriana E Rosato; James M Musser
Journal:  Antimicrob Agents Chemother       Date:  2014-08-25       Impact factor: 5.191

2.  Heterogeneity of methicillin-resistant Staphylococcus aureus strains (MRSA) characterized by flow cytometry.

Authors:  Tomasz Jarzembowski; Katarzyna Wiśniewska; Agnieszka Jóźwik; Jacek Witkowski
Journal:  Curr Microbiol       Date:  2009-03-28       Impact factor: 2.188

3.  Identification of point mutations in clinical Staphylococcus aureus strains that produce small-colony variants auxotrophic for menadione.

Authors:  Melissa A Dean; Randall J Olsen; S Wesley Long; Adriana E Rosato; James M Musser
Journal:  Infect Immun       Date:  2014-01-22       Impact factor: 3.441

4.  Ceftaroline is active against heteroresistant methicillin-resistant Staphylococcus aureus clinical strains despite associated mutational mechanisms and intermediate levels of resistance.

Authors:  Regina Fernandez; Liliana I Paz; Roberto R Rosato; Adriana E Rosato
Journal:  Antimicrob Agents Chemother       Date:  2014-07-14       Impact factor: 5.191

5.  Fate of mutation rate depends on agr locus expression during oxacillin-mediated heterogeneous-homogeneous selection in methicillin-resistant Staphylococcus aureus clinical strains.

Authors:  Konrad B Plata; Roberto R Rosato; Adriana E Rosato
Journal:  Antimicrob Agents Chemother       Date:  2011-05-02       Impact factor: 5.191

6.  VraSR two-component regulatory system contributes to mprF-mediated decreased susceptibility to daptomycin in in vivo-selected clinical strains of methicillin-resistant Staphylococcus aureus.

Authors:  Shrenik Mehta; Arabela X Cuirolo; Konrad B Plata; Sarah Riosa; Jared A Silverman; Aileen Rubio; Roberto R Rosato; Adriana E Rosato
Journal:  Antimicrob Agents Chemother       Date:  2011-10-10       Impact factor: 5.191

7.  A low-affinity penicillin-binding protein 2x variant is required for heteroresistance in Streptococcus pneumoniae.

Authors:  Hansjürg Engel; Moana Mika; Dalia Denapaite; Regine Hakenbeck; Kathrin Mühlemann; Manfred Heller; Lucy J Hathaway; Markus Hilty
Journal:  Antimicrob Agents Chemother       Date:  2014-04-28       Impact factor: 5.191

8.  Development of homogeneous expression of resistance in methicillin-resistant Staphylococcus aureus clinical strains is functionally associated with a beta-lactam-mediated SOS response.

Authors:  Arabela Cuirolo; Konrad Plata; Adriana E Rosato
Journal:  J Antimicrob Chemother       Date:  2009-05-20       Impact factor: 5.790

9.  Hemoculture and Direct Sputum Detection of mecA-Mediated Methicillin-Resistant Staphylococcus aureus by Loop-Mediated Isothermal Amplification in Combination With a Lateral-Flow Dipstick.

Authors:  Kawin Nawattanapaiboon; Photchanathorn Prombun; Pitak Santanirand; Apirom Vongsakulyanon; Toemsak Srikhirin; Boonsong Sutapun; Wansika Kiatpathomchai
Journal:  J Clin Lab Anal       Date:  2016-03-17       Impact factor: 2.352

10.  Spontaneous deletion of the methicillin resistance determinant, mecA, partially compensates for the fitness cost associated with high-level vancomycin resistance in Staphylococcus aureus.

Authors:  Michael J Noto; Paige M Fox; Gordon L Archer
Journal:  Antimicrob Agents Chemother       Date:  2008-01-22       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.